Edgar Filing: MYRIAD GENETICS INC - Form 4

MYRIAD GH	ENETICS INC											
Form 4												
September 16	6, 2016											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL		
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check this if no long subject to	1ENT OF	CHANGES IN BENEFICIAL OWN						NERSHIP OF	Expires: Estimated a	January 31 2005 overage		
Section 10	Section 16. SECURITIES Form 4 or							burden hou response	rs per			
Form 5	· ·							•	e Act of 1934,			
obligations may continue.Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).												
(Print or Type R	esponses)											
Wenstrup Richard Symb				2. Issuer Name and Ticker or Trading mbol [YRIAD GENETICS INC [MYGN]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (I							1011	(Chec	k all applicable	e)	
				Date of Earliest Transaction Month/Day/Year)					Director 10% Owner			
320 WAKARA WAY			09/14/2016						Officer (give title Other (specify below) below) Chief Medical Officer			
				nendment, Date Original Ionth/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
SALT LAKI	E CITY, UT 841	08								fore than One Re		
(City)	(State)	(Zip)	Table	e I - Non	ı-De	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)		Date, if	3. Transac Code (Instr. 3 Code	8)	4. Securiti n(A) or Dis (D) (Instr. 3, 4)	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	09/14/2016			A <u>(1)</u>		30,000	A	\$0	52,069	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. or/Number of Derivative Securities Acquired (A) or Disposed		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans
				of (D) (Instr. 3, 4, and 5)						(Instr
			Code V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: MYRIAD GENETICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Wenstrup Richard 320 WAKARA WAY SALT LAKE CITY, UT 84108			Chief Medical Officer					
Signatures								
By: Richard Marsh For: Richard Wenstrup	d 09/16/2016							
**Signature of Reporting Person		Da	ite					
Explanation of Dag	none							

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each (1) restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 30, 2017, 25% on September 30, 2018, 25% on September 30, 2019, and 25% on September 30, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.